Menu Search
Equities

Aclaris Therapeutics Inc

8AT:FRA

Aclaris Therapeutics Inc

Actions
  • Price (EUR)4.06
  • Today's Change0.287 / 7.61%
  • Shares traded1.42k
  • 1 Year change+417.20%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 09:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

  • Revenue in USD (TTM)27.08m
  • Net income in USD-37.00m
  • Incorporated2012
  • Employees91.00
  • Location
    Aclaris Therapeutics Inc701 Lee Road, Suite 103WAYNE 19087United StatesUSA
  • Phone+1 (484) 324-7933
  • Fax+1 (302) 655-5049
  • Websitehttps://www.aclaristx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.